Financial Daily from THE HINDU group of publications
Tuesday, Mar 09, 2004

Cross Currency

Group Sites

Marketing - New Products & Services
Industry & Economy - Health

Natco launches another anti-cancer drug

Our Bureau

Hyderabad , March 8

NATCO Pharma Ltd (NPL) has announced the launch of yet another anti-cancer drug from its stable.

The company has been tapping this segment with low-cost drugs.

In a press release here on Monday, the company said it has launched Geftinib 250 mg tablets under the brand name `Geftinat.' This is a first time introduction of the generic version of Geftinib in the country, it said.

Geftinib is a selective epidermal growth factor receptor. Natco's Geftinat aims at presenting a remedy for lung cancer. It is an effective monotherapy treatment for patients suffering from non-small cell lung cancer, the release said.

Priced at Rs 325 per tablet of 250 mg, which is said to be one-tenth of the cost of international brand presently available in the market, the company claimed that the drug was invented and patent application was filed prior to 1995.

Keeping in view the slated future launches, the company expects to catapult itself into a significant position in the oncology segment, the release said.

More Stories on : New Products & Services | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Maintenance contracts for bathrooms!

Pizza Hut to scale up
Dilmah Tea scouts for ad agency in India
Grey bags Emirates' South Asia account
ESPN-Star Sports to play up hockey — Plans live telecasts
Visa promotion plan for travellers to Singapore
Despite new rollouts, car dealers are not smiling
Dandi salt, Friendly Wash to go off the shelves
Tata AIG launches unit-linked plan
Richie launches new tadalafil version
Natco launches another anti-cancer drug
McDowell uncorks Old Cask rum in Karnataka

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line